{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"46.7"}]}],"title":"Anemia: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5"},{"groupId":"OG001","value":"27.9"}]}],"title":"Anemia: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"10.9"}]}],"title":"Anemia: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"},{"groupId":"OG001","value":"3.0"}]}],"title":"Hemoglobin increased: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"}]}],"title":"Hemoglobin increased: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5"},{"groupId":"OG001","value":"1.2"}]}],"title":"Lymphocyte count increased: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1"},{"groupId":"OG001","value":"26.1"}]}],"title":"Lymphopenia: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7"},{"groupId":"OG001","value":"33.9"}]}],"title":"Lymphopenia: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6"},{"groupId":"OG001","value":"13.9"}]}],"title":"Lymphopenia: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"1.8"}]}],"title":"Lymphopenia: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6"},{"groupId":"OG001","value":"14.5"}]}],"title":"Neutrophils (Absolute): Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"26.7"}]}],"title":"Neutrophils (Absolute): Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1"},{"groupId":"OG001","value":"13.9"}]}],"title":"Neutrophils (Absolute): Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"3.6"}]}],"title":"Neutrophils (Absolute): Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"21.8"}]}],"title":"Platelets: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"7.9"}]}],"title":"Platelets: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"7.9"}]}],"title":"Platelets: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.6"}]}],"title":"Platelets: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5"},{"groupId":"OG001","value":"34.5"}]}],"title":"White blood cells: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9"},{"groupId":"OG001","value":"24.2"}]}],"title":"White blood cells: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"},{"groupId":"OG001","value":"9.1"}]}],"title":"White blood cells: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.6"}]}],"title":"White blood cells: Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"Anemia(grade\\[g\\]1:Less than\\[\\<\\] Lower limit of normal\\[LLN\\] to 10gram per\\[/\\] deciliter\\[g/dL\\],g2:\\<10 to 8g/dL,g3:\\<8g/dL,g4:lifethreatening);platelet (g1:\\<LLN to 75\\*10\\^3/millimeter\\[mm\\]\\^3,g2:\\<75\\*10\\^3/mm\\^3 to 50\\*10\\^3/mm\\^3,g3:\\<50\\*10\\^3/mm\\^3 to 25\\*10\\^3/mm\\^3,g4:\\<25\\*10\\^3/mm\\^3);lymphopenia(g1:\\<LLN to 8\\*10\\^2/mm\\^3,g2:\\<8\\*10\\^2 to 5\\*10\\^2/mm\\^3,g3:\\<5\\*10\\^2 to 2\\*10\\^2/mm\\^3,g4:\\<2\\*10\\^2/mm\\^3);neutrophil (Absolute)(g1:\\<LLN to 15\\*10\\^2/mm\\^3,g2:\\<15\\*10\\^2 to 10\\*10\\^2/mm\\^3,g3:\\<10\\*10\\^2 to 5\\*10\\^2/mm\\^3,g4:\\<5\\*10\\^2/mm\\^3);white blood cell count(g1:\\<LLN to 3\\*10\\^3/mm\\^3,g2:\\<3\\*10\\^3 to 2\\*10\\^3/mm\\^3,g3:\\<2\\*10\\^3 to 1\\*10\\^3/mm\\^3,g4:\\<1\\*10\\^3/mm\\^3);hemoglobin(g1:increase in hemoglobin level\\>0 to 2 g/dL above ULN or above baseline if baseline is above ULN,g2:increase in hemoglobin level\\>2 to 4g/dL above ULN or above baseline if baseline is above ULN,g3:increase in hemoglobin level\\>4 g/dL above ULN or above baseline if baseline is above ULN). Only categories with atleast 1 participant with abnormality are reported in this outcome measure.","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"},{"description":"Standard doses of chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) were administered intravenously on Day 1 of each cycle for a maximum of 6 cycles. Pemetrexed 500 mg per meter square (m)\\^2 IV infusion according to standard of care was administered over 10 min; either cisplatin 75 mg/m\\^2 IV infusion was administered approximately 30 min after the end of the pemetrexed infusion or carboplatin was administered at a dose calculated to produce an AUC of 5 or 6 mg\\*min/mL, approximately 30 min after end of pemetrexed infusion.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Safety analysis population included all randomized subjects who received at least 1 dose of study treatment, with treatment assignments designated according to actual study treatment received during the first cycle. Here, N=participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to follow up period (up to 72 months)","title":"Percentage of Participants With Laboratory Test Abnormalities By Maximum Severity: National Cancer Institute Common Terminology Criteria for Adverse Event (Version 4.0) Grade 1 to 4 Hematological Test Abnormalities","type":"SECONDARY","unitOfMeasure":"percentage of participants"}